Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients.

CPT: pharmacometrics & systems pharmacology - 1 Jul 2023

Chen Di, Yao Qingyu, Chen Wenjun, Yin Jian, Hou Shifang, Tian Xiaoxin, Zhao Ming, Zhang Hua, Yang Liping, Zhou Tianyan, Jin Pengfei

Abstract excerpt

Tacrolimus is an important immunosuppressant used in the treatment of myasthenia gravis (MG). However, the population pharmacokinetic (PK) characteristics together with the exposure-response of tacrolimus in the treatment of MG remain largely unknown. In this study, we aimed to develop a population PK/pharmacodynamic (PK/PD) model of tacrolimus in patients with MG, in order to explore the relationships among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Models, Biological

Share to Myasthenia Gravis

Share to Tacrolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 37060188
DOI: 10.1002/psp4.12966
PMCID: PMC10349186

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients.PMID 37060188Read ↗

Population Pharmacokinetics and Dose Optimization of Tacrolimus in Chinese Adult Patients with Myasthenia GravisSemantic proximity Read ↗

Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.Semantic proximity Read ↗

Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review.Semantic proximity Read ↗

Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.Semantic proximity Read ↗

Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients.Semantic proximity Read ↗

Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.Semantic proximity Read ↗

Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.Semantic proximity Read ↗

HLA-A*11:01 and HLA-C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups.Semantic proximity Read ↗

Pharmacogenomics-based tacrolimus combined with Wuzhi capsules in precision medicine in kidney transplant patientsSemantic proximity Read ↗

Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.Semantic proximity Read ↗

Population Pharmacokinetic Models for Tacrolimus in non-transplant patients: A Systematic ReviewSemantic proximity Read ↗

Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.